✦ LIBER ✦

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

✍ Scribed by David Scott Miller; John A. Blessing; Diane C. Bodurka; Albert J. Bonebrake; John O. Schorge

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II evaluation of pemetrexed (Ali

✍ David Scott Miller; John A. Blessing; Richard D. Drake; Robert Higgins; D. Scott 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 235 KB

A Phase II evaluation of weekly topoteca

✍ James V. Fiorica; John A. Blessing; Louis V. Puneky; Angeles Alvarez Secord; Jam 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Evaluation of vinorelbine in persistent

✍ Franco M. Muggia; John A. Blessing; Steven Waggoner; Jonathan S. Berek; Bradley 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 83 KB

A phase II evaluation of flavopiridol as

✍ Edward C. Grendys Jr.; John A. Blessing; Robert Burger; James Hoffman 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 92 KB

Evaluation of vinorelbine in persistent

✍ Franco M Muggia; John A Blessing; Michael Method; David Scott Miller; Gary A Joh 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Evaluation of tamoxifen in persistent or

✍ L. R. Bigler; J. Tate Thigpen; J. A. Blessing; J. Fiorica; B. J. Monk 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB